Anebulo Pharmaceuticals (ANEB) Q4 2025 Financial Results Summary

# Anebulo Pharmaceuticals (ANEB) Q4 2025 Financial Results Summary

**Release Date: September 29, 2025**

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company dedicated to developing novel solutions for individuals experiencing acute cannabis-induced toxicity, has released its financial results for the fourth quarter and fiscal year 2025, along with recent updates. The following summary outlines the key highlights and metrics from the report:

## Fourth Quarter Fiscal Year 2025 Highlights

– **Phase 1 Study Announcement:**
– On September 25, 2025, Anebulo announced that the first subjects had been dosed in a Phase 1 study of an intravenous (IV) formulation of its lead drug candidate, selonabant, aimed at treating acute cannabis-induced toxicity in children.
– The study was designed as a randomized, double-blind, placebo-controlled trial approved by the FDA and is conducted in Austin, Texas.

– **NIDA Grant Award:**
– Anebulo received a second-year tranche of $994,300 from the National Institute on Drug Abuse (NIDA) to support the ongoing SAD study of selonabant.

– **CEO Commentary:**
– CEO Richie Cunningham emphasized significant progress towards developing a treatment for acute cannabis-induced toxicity in children, highlighting the FDA’s supportive stance on the company’s focused development of selonabant.

## Financial Results for the Three Months Ended June 30, 2025

– **Operating Expenses:**
– Q4 operating expenses were **$2.3 million**, representing a **77% increase** from **$1.3 million** in Q4 2024.

– **Net Loss:**
– The net loss was **$2.1 million**, leading to a net loss per share of **$(0.05)**, which was the same as in Q4 2024, where the loss was also **$1.3 million**.

– **Cash Position:**
– Cash and cash equivalents were **$11.6 million** as of June 30, 2025, compared to **$3.1 million** as of June 30, 2024.

## Financial Results for the Twelve Months Ended June 30, 2025

– **Operating Expenses:**
– Total operating expenses for FY 2025 amounted to **$9.2 million**, marking an **increase of 10.7%** from **$8.3 million** in FY 2024.

– **Research and Development Costs:**
– R&D expenses rose by approximately **$0.9 million** primarily due to increased activities related to clinical studies and costs associated with contract research organizations (CROs) and contract manufacturing organizations (CMOs).

– **Net Loss:**
– The fiscal year net loss was **$8.5 million**, or **$(0.25)** per share, compared to a loss of **$8.2 million**, or **$(0.32)** per share in 2024. This indicates a **3.7% increase** in net loss year-over-year.

## Additional Updates

– **Reverse Stock Split:**
– A Special Committee of independent directors proposed a reverse stock split to keep the number of record holders below 300, to avoid mandatory SEC reporting. The approval will require stockholder consent at a future special meeting.

– **Stock Performance:**
– The weighted average common shares outstanding increased to **41.08 million** in Q4 2025 versus **25.93 million** in Q4 2024.

## Summary of Key Financial Metrics

Anebulo Pharmaceuticals is continuing to prioritize the advancement of selonabant as a potential treatment for pediatric patients facing cannabis toxicity. The focus on a faster drug approval timeline for the IV formulation reflects the company’s commitment to addressing this significant unmet medical need.

Here are the extracted tables from the press release in Markdown format.

### Condensed Statements of Operations (in thousands)

### Condensed Balance Sheets (in thousands)